In brief: Acrux, Proteome Systems, Panbio, Virax
Tuesday, 31 January, 2006
Ross Dobinson has been appointed as Acrux's (ASX:ACR) non-executive chairman, replacing Nuno D'Aquino who is stepping down due to private commitments. D'Aquino will continue as a non-executive director and will chair the board's Human Capital Committee.
Dobinson is a founder and former CEO of Acrux and has an 8 per cent interest in the company's shares. Ken Windle, an Acrux director since 2001, has been appointed non-executive deputy chairman.
Following a letter of intent announced at BIO 2005, Proteome Systems (ASX:PXL) has signed a formal agreement with the Bill Gates-funded Foundation for Innovative New Diagnostics (FIND) to develop Proteome's tuberculosis biomarkers for incorporation into a point-of-care test. The agreement details development milestones and financial and non-financial commitments.
Panbio (ASX:PBO) has appointed Peter Burrows as CFO and company secretary permanently. He was originally appointed on an interim basis on August 27.
Virax Holdings (ASX:VHL) has raised a further $600,000 under its rights issue, bringing the total raised to $3.7 million out of $3.8 million. The issue will close on February 15.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
